Article Figures & Data
Tables
Administered activity (intravenous) Largest radiation dose Effective dose Radiopharmaceutical MBq mCi Organ mGy/MBq rad/mCi mSv/MBq rem/mCi 99mTc-DTPA (24) 555–1,110 15–30 Bladder wall 0.065 0.24 0.0063 0.023 99mTc-HMPAO (25) 370–1,110 10–30 Kidneys 0.034 0.0126 0.0093 0.034 99mTc-ECD 370–1,110 10–30 Bladder wall 0.05 0.18 0.0077 0.028 Administered activity (intravenous) Minimum dose Maximum dose Largest radiation dose Effective dose Radiopharmaceutical MBq/kg mCi/kg MBq mCi MBq mCi Organ mGy/MBq rad/mCi mSv/MBq rem/mCi 99mTc-DTPA (24) 7.4 0.2 370 10 740 20 Bladder wall 0.17 0.63 0.017 0.063 99mTc-HMPAO (25) 11.1 0.3 185 5 740 20 Thyroid 0.14 0.52 0.027 0.099 99mTc-ECD (26) 11.1 0.3 185 5 740 20 Bladder wall 0.11 0.41 0.022 0.081 Fetal dose Stage of gestation mGy/MBq rad/mCi mGy rad Early 0.012 0.044 6.7–8.9 0.67–0.89 3 mo 0.0087 0.032 4.8–6.4 0.48–0.64 6 mo 0.0041 0.015 2.3–3.0 0.23–0.30 9 mo 0.0047 0.017 2.6–3.5 0.26–0.35 Dose estimates to fetus were provided by Russell et al. (27). Information about possible placental crossover of this compound was included in the calculations.
Fetal dose Stage of gestation mGy/MBq rad/mCi mGy rad Early 0.0087 0.032 3.2–9.7 0.32–0.97 3 mo 0.0067 0.025 2.5–7.4 0.25–0.74 6 mo 0.0048 0.018 1.8–5.3 0.18–0.53 9 mo 0.0036 0.013 1.3–4.0 0.13–0.40 Dose estimates to fetus were provided by Russell et al. (27). No information about possible placental crossover of this compound was available.
Jump to section
- Article
- PREAMBLE
- I. INTRODUCTION
- II. GOALS
- III. DEFINITIONS
- IV. COMMON CLINICAL INDICATIONS
- V. QUALIFICATIONS AND RESPONSIBILITES OF PERSONNEL (IN THE UNITED STATES)
- VI. PROCEDURE/SPECIFICATIONS OF THE EXAMINATION
- VII. DOCUMENTATION/REPORTING
- VIII. EQUIPMENT SPECIFICATION
- IX. QUALITY CONTROL AND IMPROVEMENT
- X. RADIATION SAFETY IN IMAGING
- Acknowledgments
- XIII. APPROVAL
- Footnotes
- XII. REFERENCES
- Figures & Data
- Info & Metrics